When PwC's US employees logged in to renew their annual benefits last month, many discovered that one item had quietly disappeared from the menu: coverage for weight-loss drugs. Starting in July, the Big Four accounting and consulting firm will no longer pay for GLP-1 medications — the class that includes Ozempic and Wegovy — unless an employee has been diagnosed with type 2 diabetes or another condition that meets established medical standards of care. For weight loss alone, employees are now on their own.
PwC is not the first major employer to make this move, and it almost certainly won't be the last. The company joins a growing list of US firms scaling back access to GLP-1s as their bills for the drugs balloon. In a statement, PwC framed the decision as a response to 'broader industry trends' and the need to manage 'rapidly rising costs' while keeping its overall benefits package 'sustainable over time.'
The numbers behind that decision are striking. A 2024 survey by the Peterson Center on Healthcare and the research group KFF found that 43 percent of large US employers covered GLP-1s for weight loss — up from just 28 percent the year before. But that same survey reported a problem the actuaries hadn't prepared for: many companies said employee usage was 'higher than expected,' driving prescription drug costs sharply upward. Effectiveness, in other words, became a budget crisis. The drugs work; people want them; insurers can't keep up.
The GLP-1 market itself is unusually concentrated. Two pharmaceutical companies — the American firm Eli Lilly and the Danish firm Novo Nordisk — dominate sales, and weight-loss drugs are now the top-selling category in the entire pharmaceutical industry. Both companies have signed deals with President Donald Trump aimed at lowering US prices, but even at reduced prices the medications remain expensive enough to strain employer-sponsored health plans, which currently cover roughly half of all Americans.
For PwC employees, the change has felt personal rather than financial. Several spoke to the Financial Times anonymously, framing the cutback in moral terms. 'They basically want us to wait to become diabetic,' one said, arguing the policy effectively discriminates against workers whose weight problems are worsened by long hours of sedentary work. 'We work so hard and do such long hours sitting in front of a computer, it is not conducive to an active lifestyle,' the same employee added. 'I don't think the obesity diagnosis is being treated respectfully.' Another called the decision 'greedy,' saying GLP-1 coverage had been one reason they recently joined the firm — and that they now felt 'stupid for signing with them.'
The broader question PwC's decision raises is one US healthcare has been dodging for years. When a medication is highly effective and in enormous demand but also costs roughly $1,000 a month per patient, who pays? Employers say they cannot indefinitely shoulder costs that blow past every projection. Employees argue that effectiveness is exactly the reason coverage should expand, not shrink. Pharmaceutical companies sit in the middle, charging what the market will bear. With more blockbuster treatments on the horizon — for Alzheimer's, for genetic conditions, for further uses of GLP-1s themselves — the PwC episode looks less like an isolated cost-cutting story and more like a preview. The boundary between what insurance treats as 'medically necessary' and what it dismisses as 'lifestyle' is about to become one of the most consequential lines in American economic life.
A miracle drug that helps millions lose weight is colliding with a brutal corporate reality: somebody has to pay for it, and employers are increasingly saying 'not us.'
PwC, one of the world's 'Big Four' accounting firms, just told its US employees that starting in July it will stop covering GLP-1 weight-loss drugs like Ozempic and Wegovy through its health insurance — unless the employee has type 2 diabetes. Workers found out when they went to renew their annual benefits, and many are furious.
PwC isn't alone. A 2024 survey by the Peterson Center on Healthcare and KFF found that 43% of large US employers cover GLP-1s for weight loss (up from 28% the year before), but many are now reporting that usage — and costs — blew past their projections. PwC framed the change as necessary to keep coverage 'sustainable over time.'
This is a classic insurance-economics problem: a product so popular and so effective that it breaks the math of who pays for it.
When you start your first salaried job, the health-insurance package will quietly shape decisions you don't yet think about — what doctors you see, what medications you can afford, even whether you stay at a job you'd otherwise leave. The PwC story is a preview: as new blockbuster treatments arrive (gene therapies, Alzheimer's drugs, more GLP-1 indications), employers will keep redrawing the line between 'medically necessary' and 'lifestyle.' That line determines what your benefits actually cover.
GLP-1s may end up being the first drug class to force a real reckoning with America's employer-based healthcare system. If 30-40% of adults qualify as obese and an effective treatment exists, but no one can agree on who pays, expect bigger fights ahead: government negotiation, insurance mandates, or a shift toward direct-to-consumer pricing. Watch whether other Big Four firms — Deloitte, EY, KPMG — follow PwC. In corporate benefits, once one prestige employer cuts something, the rest often quietly follow within a year.